<DOC>
	<DOCNO>NCT00487708</DOCNO>
	<brief_summary>This study investigate clinical efficacy , safety , pharmacokinetics ( PK ) pharmacodynamics ( PD ) ACZ885 , administer intravenously subcutaneously patient NALP3 mutation whose clinical symptom either untreated insufficiently treat require medical intervention .</brief_summary>
	<brief_title>Safety , Efficacy , Pharmacokinetics , Pharmacodynamics ACZ885 Patients With NALP3 Mutations Clinical Symptoms</brief_title>
	<detailed_description />
	<criteria>Patients age 4 75 year ( inclusive ) Body weight ≥ 12 kg &lt; 100 kg . Females childbearing potential must negative pregnancy test . Additional birth control detail provide screen . Documented molecular diagnosis NALP3 mutation clinical symptom either untreated insufficiently treat require medical intervention . Patients anakinra therapy IL1 block therapy , whose clinical symptom improve treatment willing discontinue therapy relapse become evident . Patients severe characteristic require oral prednisone eligible dose stable ( ≤ 0.4 mg/kg/day ≤ 20 mg/day , whichever low ) least 1 week prior screen visit . Steroid therapy may taper treatment ACZ885 discretion investigator . Parents ' legal guardian 's write informed consent ( patient 's informed consent ≥ 18 year age ) child 's assent , appropriate , require prior study participation . Participation clinical trial investigation ( except trial anakinra ) within 4 week prior dose long per local regulation Antiinflammatory therapy colchicine , chlorambucil , dapsone , azathioprine , mycophenolate mofetil , within 3 week prior dose . Therapeutic antibody ( e.g . antiTNFalpha antibody ) must discontinue least 60 day dose . Donation loss 400 mL blood within 8 week prior dose . A past personal close family medical history clinically significant ECG abnormality prolong QTinterval syndrome . History Immunocompromise , include positive HIV result . Positive Hepatitis B surface antigen Hepatitis C test result . Drug alcohol abuse within 12 month prior dose . Tuberculosis . Renal transplant . Evidence lymphoma . Active medical condition prevent participation study infection , poorly control diabetes etc . No live vaccination within 3 month prior start trial , trial , 3 month follow last dose .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>ACZ885</keyword>
	<keyword>NALP3 mutation</keyword>
	<keyword>Interleukin-1beta</keyword>
	<keyword>Muckle-Wells Syndrome</keyword>
</DOC>